Stefano Cascinu

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Eric Van Cutsem, Claus-Henning Köhne, István Láng et al. · Journal of Clinical Oncology · 2011 · 1.9K citations · Full text

Medicine, Oncology, Pharmacology +17

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Florian Lordick, Fátima Carneiro, Stefano Cascinu et al. · Annals of Oncology · 2022 · 1.4K citations · Full text

Medicine, Oncology, Surgery +14

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

Timothy Price, Marc Peeters, Tae Won Kim et al. · The Lancet Oncology · 2014 · 470 citations · Full text

Medicine, Oncology, Pharmacology +9

Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial

Stefano Cascinu, Vincenzo Catalano, L. Cordella et al. · Journal of Clinical Oncology · 2002 · 416 citations

Medicine, Oncology, Pharmacology +17

PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

Fotios Loupakis, Luca Emanuele Pollina, I. Stasi et al. · Journal of Clinical Oncology · 2009 · 404 citations · Full text

Medicine, Oncology, Pharmacology +17